Literature DB >> 17906644

Modifying IGF1 activity: an approach to treat endocrine disorders, atherosclerosis and cancer.

David R Clemmons1.   

Abstract

Insulin-like growth factor 1 (IGF1) is a polypeptide hormone that has a high degree of structural similarity to human proinsulin. Owing to its ubiquitous nature and its role in promoting cell growth, strategies to inhibit IGF1 actions are being pursued as potential adjunctive measures for treating diseases such as short stature, atherosclerosis and diabetes. In addition, most tumour cell types possess IGF1 receptors and conditions in the tumour microenvironment, such as hypoxia, can lead to enhanced responsiveness to IGF1. Therefore, inhibiting IGF1 action has been proposed as a specific mechanism for potentiating the effects of existing anticancer therapies or for directly inhibiting tumour cell growth.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17906644     DOI： 10.1038/nrd2359

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


  122 in total

Review 1.  Lung cancer therapeutics that target signaling pathways: an update.

Authors:  M Roshni Ray; David Jablons; Biao He
Journal:  Expert Rev Respir Med       Date:  2010-10       Impact factor: 3.772

Review 2.  The endoplasmic reticulum protein folding factory and its chaperones: new targets for drug discovery?

Authors:  Martin McLaughlin; Koen Vandenbroeck
Journal:  Br J Pharmacol       Date:  2011-01       Impact factor: 8.739

3.  PDK1 recruitment to the SHPS-1 signaling complex enhances insulin-like growth factor-i-stimulated AKT activation and vascular smooth muscle cell survival.

Authors:  Xinchun Shen; Gang Xi; Yashwanth Radhakrishnan; David R Clemmons
Journal:  J Biol Chem       Date:  2010-07-19       Impact factor: 5.157

4.  N-cadherin upregulation mediates adaptive radioresistance in glioblastoma.

Authors:  Satoru Osuka; Dan Zhu; Zhaobin Zhang; Chaoxi Li; Christian T Stackhouse; Oltea Sampetrean; Jeffrey J Olson; G Yancey Gillespie; Hideyuki Saya; Christopher D Willey; Erwin G Van Meir
Journal:  J Clin Invest       Date:  2021-03-15       Impact factor: 14.808

5.  IGF1 Shapes Macrophage Activation in Response to Immunometabolic Challenge.

Authors:  Olga Spadaro; Christina D Camell; Lidia Bosurgi; Kim Y Nguyen; Yun-Hee Youm; Carla V Rothlin; Vishwa Deep Dixit
Journal:  Cell Rep       Date:  2017-04-11       Impact factor: 9.423

6.  Syndecan-1 couples the insulin-like growth factor-1 receptor to inside-out integrin activation.

Authors:  DeannaLee M Beauvais; Alan C Rapraeger
Journal:  J Cell Sci       Date:  2010-11-01       Impact factor: 5.285

Review 7.  Role of the GH/IGF-1 axis in lifespan and healthspan: lessons from animal models.

Authors:  Darlene E Berryman; Jens Sandahl Christiansen; Gudmundur Johannsson; Michael O Thorner; John J Kopchick
Journal:  Growth Horm IGF Res       Date:  2008-08-16       Impact factor: 2.372

8.  Identification of novel SHPS-1-associated proteins and their roles in regulation of insulin-like growth factor-dependent responses in vascular smooth muscle cells.

Authors:  Xinchun Shen; Gang Xi; Yashwanth Radhakrishnan; David R Clemmons
Journal:  Mol Cell Proteomics       Date:  2009-03-18       Impact factor: 5.911

9.  Design of an insulin analog with enhanced receptor binding selectivity: rationale, structure, and therapeutic implications.

Authors:  Ming Zhao; Zhu-li Wan; Linda Whittaker; Bin Xu; Nelson B Phillips; Panayotis G Katsoyannis; Faramarz Ismail-Beigi; Jonathan Whittaker; Michael A Weiss
Journal:  J Biol Chem       Date:  2009-09-22       Impact factor: 5.157

10.  Insulin-like growth factor (IGF) signaling requires αvβ3-IGF1-IGF type 1 receptor (IGF1R) ternary complex formation in anchorage independence, and the complex formation does not require IGF1R and Src activation.

Authors:  Masaaki Fujita; Yoko K Takada; Yoshikazu Takada
Journal:  J Biol Chem       Date:  2012-12-14       Impact factor: 5.157
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.